Progress and diagnostic value of related biomarkers in acute exacerbation of chronic obstructive pulmonary disease

doi:10.3877/cma.j.issn.2095-655X.2015.02.013

Abstract

Abstract:

Chronic obstructive pulmonary disease(COPD) is a common lung disease in clinic, and its acute exacerbation (AECOPD) is one of the important cause of death in the elderly.Earlier diagnosis and treatment is vital for preventing the development of diseases and improving prognosis.Studies have shown that AECOPD may be related to protease-antiprotease imbalances, oxidative stress, inflammation, and cell damage and so on, so the study of related biomarkers can help assess the severity and the treatment of the illness.Innovative sampling techniques which mainly include non-invasive, semi-invasive and invasive methods have led to the identification of several pulmonary biomarkers in the past decade.Pulmonary biomarkers are sampled in the exhaled air, exhaled breath condensate, spontaneous sputum, induced sputum, bronchoalveolar lavage fluid and lung biopsies.This article try to highlight the reciprocal links and illustrate the clinical effects of these biomarkers, expecting to contribute to the more significant clinical assessment in AECOPD and provide more references for treatment options.

Key words: Pulmonary disease, chronic obstructive, Biological markers, Inflammation, Cytokines

Kai Guo, Shaojun Yin. Progress and diagnostic value of related biomarkers in acute exacerbation of chronic obstructive pulmonary disease[J]. Chinese Journal of Diagnostics(Electronic Edition), 2015, 03(02): 133-137.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2015.02.013

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2015/V03/I02/133

References 33

[1]	Cazzola M,MacNee W,Martinez FJ, et al.Outcomes for COPD pharmacological trials：from lung function to biomarkers[J]. Eur Respir J, 2008, 31(2): 416-469.
[2]	Biomarkers Definitions Working Group.Biomarkers and surrogate endpoints：preferred definitions and conceptual framework[J]. Clin Pharmacol Ther, 2001, 69(3): 89-95.
[3]	Shorter JH,Nelson DD,McManus JB, et al.Clinical study of multiple breath biomarkers of asthma and COPD (NO, CO(2), CO and N(2)O) by infrared laser spectroscopy[J]. J Breath Res, 2011, 5(3): 037108.
[4]	Agusti AG,Villaverde JM,Togores B, et al.Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease[J]. Eur Respir J, 1999, 14(3): 523-528.
[5]	Al-Ali MK,Howarth PH.Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia[J]. Saudi Med J, 2001, 22(3): 249-253.
[6]	Papi A,Bellettato CM,Braccioni F, et al.Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations[J]. Am J Respir Crit Care Med, 2006, 173(10): 1114-1121.
[7]	De Laurentiis G,Maniscalco M,Cianciulli F, et al.Exhaled nitric oxide monitoring in COPD using a portable analyzer[J]. Pulm Pharm acol Ther, 2008, 21(4): 689-693.
[8]	Antus B,Barta I,Horvath I, et al.Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations[J]. Respirology, 2010, 15(3): 472-477.
[9]	Antus B,Barta I,Kullmann T, et al.Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease：a longitudinal study[J]. Am J Respir Crit Care Med, 2010, 182(12): 1492-1497.
[10]	Cosio BG,Iglesias A,Rios A, et al.Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD[J]. Thorax, 2009, 64(5): 424-429.
[11]	Corhay JL,Henket M,Nguyen D, et a1.Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD[J]. Chest, 2009, 136(4): 1047-1054.
[12]	Montnsehi P,Collins JV,Ciabattoni G, et al.Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers[J]. Am J Respir Crit Care Med, 2000, 162(3 Pt 1): 1175-1177.
[13]	Ko FW,Leung TF,Wong GW, et al.Measurement of tumor necrosis factor-α, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2009(4): 79-86.
[14]	Koutsokera A,Kiropoulos TS,Nikoulis DJ, et al.Clinical, functional and biochemical changes during recovery from COPD exacerbations[J]. Respir Med, 2009, 103(6): 919-926.
[15]	Mazur W,Stark H,Sovijarvi A, et al.Comparison of 8-isoprostane and interleukin-8 in induced sputum and exhaled breath condensate from asymptomatic and symptomatic smokers[J]. Respiration, 2009, 78(2): 209-216.
[16]	Carpagnano GE,Resta O,Foschino-Barbaro MP, et al.Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease：effect of carbocysteine lysine salt monohydrate (SCMC-Lys)[J]. Eur J Pharmacol, 2004, 505(1-3): 169-175.
[17]	Antczak A,Ciebiada M,Pietras T, et al.Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease[J]. Arch Med Sci, 2012, 8(2): 277-285.
[18]	Sethi S,Wrona C,Eschberger K, et al.Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2008, 177(5): 491-497.
[19]	Parameswaran GI,Sethi S,Murphy TF.Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD[J]. Chest, 2011, 140(3): 611-617.
[20]	Brusse-Keizer MG,Grotenhuis AJ,Kerstjens HA, et al.Relation of sputum colour to bacterial load in acute exacerbations of COPD[J]. Respir Med, 2009, 103(4): 601-606.
[21]	Hurst JR,Perera WR,Wilkinson TM, et al.Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2006, 173(1): 71-78.
[22]	Sethi S,Muscarella K,Evans N, et al.Airway inflammation and etiology of acute exacerbations of chronic bronchitis[J]. Chest, 2000, 118(6): 1557-1565.
[23]	O′Donnell RA,Peebles C,Ward JA, et a1.Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD[J]. Thorax, 2004, 59(10): 837-842.
[24]	Tobin MJ.Chronic obstructive pulmonary disease, pollution, pulmonary vasular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2002[J]. Am J Respir Crit Care Med, 2003, 167(3): 356-370.
[25]	Wilkinson TM,Hurst JR,Perera WR, et al.Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD[J]. Chest, 2006, 129(2): 317-324.
[26]	Pant S,Walters EH,Griffiths A, et al.Airway inflammation and anti-protease defences rapidly improve during treatment of an acute exacerbation of COPD[J]. Respirology, 2009, 14(4): 495-503.
[27]	Hodge G,Nairn J,Holmes M, et al.Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects[J]. Clin Exp Immunol, 2007, 150(1): 22-29.
[28]	Miller M,Ramsdell J,Friedman P, et al.Computed tomographic scan-diagnosed chronic obstructive pulmonary disease emphysema：eotaxin-1 is associated with bronchodilator response and extent of emphysema[J]. J Allergy Clin Immunol, 2007, 120(5): 1118-1125.
[29]	Barnes PJ,Chowdhury B,Kharitonov SA, et al.Pulmonary biomarkers in chronic obstructive pulmonary disease[J]. Am J of Respir Crit Care Med, 2006, 174(1): 6-14.
[30]	Snoeck-Stroband JB,Lapperre TS,Gosman MM, et al.Chronic bronchitis sub-phenotype within COPD：inflammation in sputum and biopsies[J]. Eur Respir J, 2008, 31(1): 70-77.
[31]	Qiu Y,Zhu J,Bandi V, et al.Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2003, 168(8): 968-975.
[32]	杨志寅. 现代医学科学发展中的缺憾和思考[J/CD]. 中华诊断学电子杂志, 2013, 1(1): 1-7.
[33]	郭凯,殷少军. 肺炎诊断相关标志物研究进展[J/CD]. 中华诊断学电子杂志, 2014, 2(2): 142-145.

Please choose a citation manager

Content to export